Emtricitabine: A new nucleoside analogue for once-daily antiretroviral therapy

Expert Opinion on Investigational Drugs

Volumn 13, Issue 1, 2004, Pages 55-68

  Cahn, Pedro ^a  

^a FUNDACIÓN HUÉSPED   (Argentina)

Author keywords

Emtricitabine; Highly active antiretroviral therapy

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FAMCICLOVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; FOOD DRUG INTERACTION; HEADACHE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INFECTION; LACTIC ACIDOSIS; LIVER TOXICITY; MELTING POINT; MOLECULAR WEIGHT; NAUSEA; REVIEW; STEADY STATE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 1642432974     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.1.55     Document Type: Review

References (47)

1. SAAG M, CAHN P, RAFFI F et al.: A randomized double-blind, multicenter comparison of emtricitabine QD to Stavudine BID. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002) (Abstract LB-1).
2. CAHN P, RAFFI F, SAAG M et al.: for the FTC-301 Study Team: virologic efficacy and patterns of resistance mutations in ART-naive patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multi-center clinical trial. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2003) (Abstract 606).
3. SANNE I, VAN DER HORST C, SHAW A et al.: Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC). XIV International AIDS Conference. Barcelona, Spain. (2002). (Abstract TuPeB4432).
4. SANNE I, QUINN JB, HARRIS J et al.: Genotypic analysis of HIV-1 infected ART-naive patients receiving emtricitabine (FTC) or lamivudine (3TC) in a double blind equivalence trial. XIV International AIDS Conference. Barcelona, Spain. (2002) (Abstract TuPeB4433).
5. PALELLA FJ, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. (1998) 338:853-860.
6. HOGG RS, HEATH KV, YIP B et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 279:450-454.
7. HOGG R, CAHN P, KATABIRA E et al.: Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 360(9347):1710-1711.
8. NO AUTHORS LISTED: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with Antiretroviral therapy. HIV Med. (2001) 2(4):276-313.
9. PATERSON DL, SWINDELLS S, MOHR J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21-30.
10. BARTLETT JA, DEMASI R, QUINN J, MOXHAM C, ROUSSEAU F: Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS (2001) 15(11):1369-1377.
11. LE MOING V, CHENE G, CARRIERI MP et al.: Aproco Study Group Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 16(1):21-29.
12. NIEUWKERK PT, SPRANGERS MAG, BURGER DM et al.: for the ATHENA Project: Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch. Intern. Med. (2001) 161:1962-1968.
13. MANNHEIMER S, FRIEDLAND G, MATTS J, CHILD C, CHESNEY M: for the Terry Beirn Community Programs for Clinical Research on AIDS: The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trails. Clin. Infect. Dis. (2002) 34(8):1115-1121.
14. ENA J, PASQUAU F: Once-a-day highly active antiretroviral therapy: a systematic review. CID (2003). 36:1186-1190.
15. FENG J et al.: Fine Tuning between antiviral activity and host toxicity: comparing the incorporation of FTC-TP analogues by HIV-1 RT and human DNA polymerase. Antimicrob. Agents Chemother. (2003) (In press).
16. USP Dictionary of USAN & Intern. Drug Names. The Dialog Corporation, NC, USA (2002):p320.
17. RICHMAN DD: Antiviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Therapy (2001) 6:83-88.
18. WANG LH, BEGLEY J, FENG JY, QUINN J, ROUSSEAU F: Pharmacokinetic and pharmacodynamic characteristics of emtricitabine supports its once daily dosing. XIV International AIDS Conference. Barcelona, Spain (2003) (Abstract 4546).
19. SCHINAZI RF: Assessment of the relative potency of emtricitabine and lamivudine. J. Acquir. Immune Defic. Syndr. (2003) 34(2):243-245.
20. ROUSSEAU FS, KAHN JO, THOMPSON M et al.: Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J. Antimicrob. Chemother. (2001) 48(4):507-513.
21. ROUSSEAU FS, WAKEFORD C, MOMMEJA-MARIN H et al.: A prospective randomized trial of emtricitabine versus lamivudine short term monotherapy in HIV-infected patients. J. Infect. Dis. (2003) 188(11):1652-1658.
22. Emtriva package insert: Gilead Sciences, July 2003.
23. SAAG M, CAHN P, RAFFI F et al.: for the FTC-301A Study Team: A randomized, double-blind, multicenter comparison of emtricitabine qd to stavudine bid. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002) (Abstract 3889).
24. CAHN P, RAFFI F, SAAG M et al.: for the FTC-301A Study Team: Virologic efficacy and patterns of resistance mutations in ART-naïve patients receiving combination therapy with daily (qd) emtricitabine compared to twice-daily (bid) stavudine in a randomized, double blind, multicenter clinical trial. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2003) (Poster 606).
25. RAFFI F, SAAG M, CAHN P et al. for the FTC-301A Study Team: A randomized, double-blind, multicenter comparison of emtricitabine qd to stavudine bid in treatment-naïve HIV-infected patients. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France (2003) (Oral presentation 1432).
26. MOLINA JM, NOE E, RAFFI F et al. and the MONTANA Study Group: Once-daily combination therapy with emtricitabine (Ftc), didanosine (Ddi) and efavirenz (Efv) In treatment naïve HIV-infected adults: 3-year follow-up of the montana (Anrs 091) trial. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France (2003) (Abstract 594).
27. MOLINA JM, FERCHALF, RANCINAN C et al.: Once-daily combination of emtricitabine, didanosine, and efavirenz vs continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial (ALIZE-ANRS 99). 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. (2003) (Abstract 551).
28. SAEZ-LLORENS X, VIOLARI A, NDIWENI D et al.: Once daily emtricitabine (FTC) in HIV-infected pediatric patients with other antiretroviral agents. 10th Conference on Retrovirus and Opportunistic Infections. Boston, MA, USA. (2003) (Abstract 872).
29. BARTLETT J oN BEHALF OF THE FTC-302 STUDY INVESTIGATORS: Severe Liver Toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. 8th Conference on Retrovirus and Opportunistic Infections, Chicago, USA (2001) (Abstract 19).
30. POWDERLY W, MONDOU E, SHAW A et al.: Overview of the incidence of symptomatic hyperlactataemia with emtricitabine (FTC). 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France. (2003) (Abstract 737).
31. POVIDERLY W, MONDOU E, SHAW A et al.: Overview of the Incidence of Symptomatic Hyperlactatemia with Emtricitabine (FTC). Antiviral Therapy (2003). 8(Suppl 1):S389.
32. SANNE I, QUINN JB, HARRIS J et al.: Genotypic analysis of HIV-1 infected ART-naive patients receiving emtricitabine (FTC) or lamivudine (3TC) in a double blind equivalence trial. XIV International AIDS Conference. Barcelona, Spain. (2002) (Abstract TuPeB4433).
33. SANNE I, ANDERSON J, KARGL D et al. for THE MKC-401 STUDY TEAM: Evaluation of emtricitabine within a triple NRTI HAART Regimen. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts, American Society for Microbiology. Chicago, USA (2003) (Abstract H-868).
34. TURNER D, BRENNER B, ROUTY J, MOISI D, WAINBERG M: Decreased rates of transmission of drug-resistant HIV-1 strains containing the M184V mutation in reverse transcriptase. Program and Abstracts of the XII International HIV Resistance Workshop: Basic Principles and Clinical Implications. Los Cabos, México. (2003) (Abstract 129)
35. WANG L, BLUM M, HUI J, HULETT G, CHITTICK E, ROUSSEAU F: Lack of significant pharmacokinetic interactions between emtricitabine and other nucleoside antivirals in healthy volunteers. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA. (200 1) (Abstract A-505).
36. BLUM MR, BEGLEY J, ZONG J, HILL D, ADDA N, CHITTICK G: Lack of a pharmacokinetic interaction between emtricitabine and tenofovir DF when coadministered to steady state in healthy volunteers. 43rd Intercience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA. (2003) (Abstract: A-1621).
37. ZONG J, BLUM MR, CHITTICK G, HART R, BROSNAN-COOK M, ADDA N: A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA. (2003) (Abstract A-1620).
38. RAFFI F, SNOW A, BORROTO-ESODA K et al.: Ani-HBV- Activity of Emtricitabine (FTC) in Patients Coinfected with HIV and Hepatitis B Virus. Antiviral Therapy. (2003) 8(Suppl 1):S236.
39. MOMMEJA-MARIN H, LEUNG N, GISH R et al.: Antiviral activity and incidence of resistance after treatment for two years with emtricitabine in patients with chronic hepatitis B. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego., CA, USA. (2002) (Abstract V-239).
40. CAHN P, RAFFI F, SAAG M et al. for the FTC-301A Study Team: Virologic efficacy and patterns of resistance mutations in ART-naïve patients receiving combination therapy with daily (qd) emtricitabine compared to twice-daily (bid) stavudine in a randomized, double blind, multicenter clinical trial. 10th Conference on Retrovirus and Opportunistic Infections. Boston, MA, USA. (2003) (Poster 606).
41. MOLINA JM, FERCHAL F, RANCINAN C et al. for the Montana (Agence Nationale de Recherches sur le SIDA 091) Study Group: Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J. Infect. Dis. (2000) 182(2):599-602.
42. WANG L: 35th Inter-Science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA. (1995) (Poster A129).
43. MOLINA JM: 2nd Inernational AIDS Society. Paris, France. (2003) (Poster 37).
44. VAN DER HORST C, SANNE I, WAKEFORD C, QUINN J, ROUSSEAU F: Two randomized, controlled, equivalence trials of emtricitibine (FTC) to lamivudine (3TC). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA. (Abstract 18).
45. WAKEFORD C, SHEN G, HULETT L, QUINN JB, ROUSSEAU F. Long-term efficacy and safety of emtricitabine in HIV+ adults switching from a lamivudine containing HAART regimen. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. (2003) (Abstract 550).
46. SANNE I, ANDERSON J, KARGL D et al. for the MKC-401 study team: Evaluation of emtricitabine within a triple NRTI HAART Regimen. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA. (2003) (Abstract H-868).
47. LANGE CG, PATTERSON BK, HARNISH B et al.: Lymphoproliferative responses to HIVp24 in chronically HIV-1 infected patients treated with HAART reflect low-level viral replication but not an improvement in indices of immune phenotype or function. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. (2003) (Abstract 345).